New trial data show tirzepatide outperforms a GLP 1 combo in weight loss, reshaping obesity drug competition, and treatment strategies.

Novo Nordisk’s B-share fell over 16 percent to 251.4 DKK, its lowest closing price since June 2021. The decline followed study data for the...

Novo Nordisk’s B-share fell over 16 percent to 251.4 DKK, its lowest closing price since June 2021. The decline followed study data for the...

The obesity drug Tirzepatide (Mounjaro/Zepbound) boosts metabolism by activating brown fat to burn calories, offering health benefits beyond weight...

LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.

With the U.S. Food and Drug Administration (FDA) recently approving GLP-1 drug Wegovy in pill form for use in weight loss and fighting obesity, the...

With the U.S. Food and Drug Administration (FDA) recently approving GLP-1 drug Wegovy in pill form for use in weight loss and fighting obesity, the...

INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a...

INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a...

NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and diabetes studies,...